openPR Logo
Press release

Dermatophytic Onychomycosis Therapeutics Market To Witness A Customized Procurement Strategy At A CAGR Of 6.5%

05-19-2022 04:37 PM CET | Health & Medicine

Press release from: Persistence Market Research

Dermatophytic Onychomycosis Therapeutics Market To Witness

The global Dermatophytic Onychomycosis Therapeutics Market is expected to reach US$ 10.30 Bn by the year 2031 at a CAGR of 6.5%. Healthcare systems have been basically emphasizing on affordability as well as quality of the medical services. However, now, digitization has come through, which would drive revolution in the same healthcare vertical. The life sciences would go digitally innovative. This would be the way healthcare vertical would go in the next 10 years.

According to the latest report published by Persistence Market Research titled "Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis 2013-2017 and Forecast 2018-2026," the dermatophytic onychomycosis therapeutics market in terms of value is expected to grow at a CAGR of 7.6% during the forecast period.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/5840

Dermatophytic onychomycosis also known as tinea guinea can have certain negative effects on patients, such as pain, and can potentially undermine their work and social lives. Moreover, the infection might spread to surrounding skin. The condition isn't considered life-threatening, but may result in physical and occupational limitations, because of which more and more number of people are opting for the treatment of their infected, thick, and cracked nails. This, in turn, is driving growth of the market for dermatophytic onychomycosis therapeutics.

The global dermatophytic onychomycosis therapeutics market based on product type has been segmented into tablets and nail paints, which is again sub-segmented into prescription (Rx) and over-the-counter. The nail paint segment is expected to contribute maximum share in the global dermatophytic onychomycosis therapeutics market and expand at a CAGR of 8.1% during the forecast period.

Based on treatment type, the global dermatophytic onychomycosis therapeutics market has been segmented into topical and oral. The topical is projected to be the dominant segment throughout the forecast period, accounting for around 70% share of the global dermatophytic onychomycosis therapeutics market by 2026.

Based on end users, the global dermatophytic onychomycosis therapeutics market has been segmented into hospitals, clinics, independent pharmacies, mail order pharmacies and drug stores. The drug stores & independent pharmacies segments are estimated to be the large segments, which collectively accounted approximately 54% share of the global dermatophytic onychomycosis therapeutics market in 2017.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/5840

The independent pharmacies segment is expected to register a high CAGR growth during the forecast period. The drug stores was the second most attractive segment in the global dermatophytic onychomycosis therapeutics market in 2017.

The growth of the market is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Dermatophytic onychomycosis is common in the elderly, with prevalence rates as high as 20% in those over 60 years of age and 30% in those over 70.

Thus increasing geriatric population is the most important factor that is expected to drive growth of the dermatophytic onychomycosis therapeutics market over the forecast period. Easy application of nail paints is also expected to drive the demand for dermatophytic onychomycosis therapeutics. Another factor fueling the growth of dermatophytic onychomycosis therapeutics market is the growing preference of dermatophytic onychomycosis therapeutics by podiatrists and dermatologists.

Rise in diagnosis of the nail infection has raised awareness regarding the fungal infection of nails and dermatophytic onychomycosis therapeutics. Besides, increasing awareness regarding dermatophytic onychomycosis therapeutics amongst podiatrists and dermatologists has led to a rise in demand for effective medications.

However, adverse effects such as headache, dizziness, nausea, stomach ache, etc., associated with antifungal drugs have made people more skeptical about practicing a systemic therapy for nails. Moreover, the topical agents also causes rash and itchiness in the surrounding skin. These side effects are hampering the acceptance of dermatophytic onychomycosis therapeutics for the treatment of moderate to severe dermatophytic onychomycosis associated with anti-fungal therapeutics.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/5840

Another factor impeding the growth of dermatophytic onychomycosis therapeutics is lack of awareness regarding dermatophytic onychomycosis therapeutics and dermatophytic onychomycosis itself. There is a general lack of awareness regarding the disease, its possible causes, symptoms etc. People in some African, European, Gulf, and Asian countries are still ignorant about their diseased nails. There is a general perception among patients that the thickened nail would get cured by itself after sometime. Thus, lack of awareness is also a major factor hindering growth of the onychomycosis therapeutics market currently.

Geographically, the global dermatophytic onychomycosis therapeutics market is segmented into five major regions, namely North America, Latin America, Europe, Asia Pacific, and Middle East & Africa (MEA). North America was the dominant regional market for dermatophytic onychomycosis therapeutics and is expected to follow the same trend over the forecast period.

The Europe market for dermatophytic onychomycosis therapeutics is expected to account for second large share followed by Asia Pacific. North America and Europe collectively are expected to account for over 60% share of the global dermatophytic onychomycosis therapeutics market over the forecast period. MEA and Latin America are expected to be the fast-growing regions in the global dermatophytic onychomycosis therapeutics market due to growing healthcare efforts.

Dermatophytic Onychomycosis Therapeutics Market: Key Players

Examples of some of the key players operating in the global dermatophytic onychomycosis therapeutics market are Valeant Pharmaceuticals Inc, Galderma S.A., Novartis AG, Pfizer Inc, Moberg Pharma AB, Johnson & Johnson Services Inc, Bayer AG, Dr. Reddy's Laboratories Ltd, Cipla Ltd, and Medimetriks Pharmaceuticals Inc.

Access Related Reports-

Antibiotic Resistance Market: https://www.persistencemarketresearch.com/market-research/antibiotic-resistance-market.asp

Microbiome Therapeutic Market: https://www.persistencemarketresearch.com/market-research/microbiome-therapeutic-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dermatophytic Onychomycosis Therapeutics Market To Witness A Customized Procurement Strategy At A CAGR Of 6.5% here

News-ID: 2630545 • Views:

More Releases from Persistence Market Research

Fruit Ingredients Market to Reach US$ 111.3 Bn by 2032, Driven by Rising Health Trends
Fruit Ingredients Market to Reach US$ 111.3 Bn by 2032, Driven by Rising Health …
Overview of the Global Fruit Ingredients Market The global fruit ingredients market is witnessing significant growth, driven by rising consumer demand for natural, clean-label, and nutrient-rich food products. In 2025, the market is likely to be valued at US$ 75.0 billion and is expected to reach US$ 111.3 billion by 2032, registering a robust CAGR of 5.8% during the forecast period. Fruit ingredients, which include fruit concentrates, purees, powders, and extracts,
Vegan Dessert Market to Reach US$ 11.9 Bn by 2032, Driven by Rising Health & Plant-Based Demand
Vegan Dessert Market to Reach US$ 11.9 Bn by 2032, Driven by Rising Health & Pla …
Overview of the Market The global vegan dessert market is poised for significant expansion, with an estimated valuation of US$ 5.2 billion in 2025, projected to reach US$ 11.9 billion by 2032. This robust growth reflects a compound annual growth rate (CAGR) of 11.7% during the forecast period from 2025 to 2032. Increasing consumer awareness about health, environmental sustainability, and ethical food consumption is driving the widespread adoption of vegan dessert
Instant Beverage Premix Market to Reach US$148.3 Bn by 2032 Driven by Convenience & Demand
Instant Beverage Premix Market to Reach US$148.3 Bn by 2032 Driven by Convenienc …
Overview of the Global Instant Beverage Premix Market The global instant beverage premix market has witnessed remarkable growth over the past decade, driven by evolving consumer lifestyles and increasing demand for convenient, ready-to-consume beverages. Instant beverage premixes, encompassing products such as instant coffee, tea, flavored drinks, protein powders, and nutritional supplements, cater to busy consumers seeking quick preparation without compromising on taste or nutritional value. These premixes have gained popularity across
Dermacosmetics Market to Reach US$ 87.3 Bn by 2032 at 7.4% CAGR: Persistence Market Research
Dermacosmetics Market to Reach US$ 87.3 Bn by 2032 at 7.4% CAGR: Persistence Mar …
The global dermacosmetics market, estimated at US$ 53 billion in 2025, is forecasted to witness a steady upward trajectory, expanding at a Compound Annual Growth Rate (CAGR) of 7.4% to reach US$ 87.3 billion by 2032. This surge is driven by a confluence of factors ranging from increasing consumer awareness and the rising incidence of skin conditions to a growing preference for advanced, dermatologist-backed skincare solutions. Dermacosmetics, a category that

All 5 Releases


More Releases for Dermatophytic

Call for Automation to Drive the Dermatophytic Onychomycosis Therapeutics Market
Advancements in medicine, diagnosis of varieties of illnesses, and increasing elder population at an unprecedented rate have resulted in high demand for novel drugs and therapies for dermatophytic onychomycosis treatment. In 2021, the dermatophytic onychomycosis therapeutics market was valued at nearly US$ 5.5 Bn, and is set to experience a 6.5% CAGR over the forecast period (2022-2031). Presence and availability of a large clinical pipeline with reference to therapeutic approaches based
Dermatophytic Onychomycosis Therapeutics (DOT) Market 2022 | Detailed Report
The research reports on “Dermatophytic Onychomycosis Therapeutics (DOT) Market” report gives detailed overview of factors that affect global business scope. Dermatophytic Onychomycosis Therapeutics (DOT) Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. An exclusive data offered in this report is collected by research and industry experts team. Download FREE Sample
Dermatophytic Onychomycosis Therapeutics (DOT) Market
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin
Dermatophytic Onychomycosis Market Expected to Witness a Sustainable Growth
According to a new report published by Allied Market Research, titled, " Dermatophytic Onychomycosis Market by Product (Nail Paint and Tablet), Route of Administration (Topical and Oral Therapy), and End User (Hospitals, Dermatology & Podiatry Clinics, Independent Pharmacies, Mail Order Pharmacies, and Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2020-2027". The global market size of Dermatophytic Onychomycosis market is $XX million in 2019 with XX CAGR, and it is
Dermatophytic Onychomycosis Market Poised to Rake US$ 4,706.3 Mn by 2021
Key players of the global dermatophytic onychomycosis therapeutics market include Galderma S.A., Valeant Pharmaceuticals International Inc., Novartis AG, Pfizer Inc., Janssen Pharmaceuticals, and others. Leading companies in this market collaborate with healthcare solutions and services providers in order to advance operational efficiencies and provide improved patient care. Persistence Market Research (PMR) delivers key insights on the global dermatophytic onychomycosis therapeutics Market in its latest report titled “Global Market Study on Dermatophytic
Dermatophytic Onychomycosis Market : Topical segment to account 70% share
The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market and expand at the fastest CAGR of 8.3% during the